Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells

BACKGROUND There is still a need for new therapeutic options against prostate cancer. Conventional single‐chain bispecific antibodies (bsAbs), that directly cross‐link T cells and tumor cells, hold great potential for efficient tumor treatment. However, rapid development of novel bsAbs is hampered b...

Ausführliche Beschreibung